InfraReDx Initiates a Randomized Clinical Trial of LipiScan IVUS(TM) Coronary Imaging Guidance to Prevent Heart Attacks During Stenting
Published: Jul 13, 2011
BURLINGTON, Mass.--(BUSINESS WIRE)--InfraReDx, Inc., a medical device company providing intelligent cardiovascular diagnostic imaging technologies, today announced enrollment of the first patient in its Phase 2 clinical trial, CANARY (Coronary Assessment by Near-infrared (NIR) of Atherosclerotic Rupture-prone Yellow). CANARY is designed to test the hypothesis that NIR-guided use of an embolic protection device (EPD), or filter, during percutaneous coronary intervention (PCI) can reduce the rate of peri-procedural heart attacks in patients identified as having high-risk lipid core plaques (HR-LCPs). InfraReDx’s LipiScan™ IVUS System is the only multimodality coronary imaging device approved in both the U.S. and Europe. It is in routine clinical use to detect the LCPs known to complicate stenting and suspected to cause most heart attacks.